Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study
Dupilumab, a human monoclonal antibody targeting the IL4 alpha receptor, is used for treatment of moderate to severe atopic dermatitis (AD). Previous studies have reported diagnoses of cutaneous T cell lymphoma (CTCL) after dupilumab use.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Iraj Hasan, Lauren Parsons, Sabrina Duran, Zachary Zinn Source Type: research
More News: Academies | Cutaneous T cell lymphoma | Dermatitis | Dermatology | Lymphoma | Skin | Study | T-cell Lymphoma